Atara Biotherapeutics, Inc. (NASDAQ:ATRA) EVP Christopher Haqq sold 1,604 shares of the company’s stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $13.36, for a total value of $21,429.44. Following the completion of the transaction, the executive vice president now owns 344,134 shares in the company, valued at $4,597,630.24. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Christopher Haqq also recently made the following trade(s):

  • On Monday, October 16th, Christopher Haqq sold 6,000 shares of Atara Biotherapeutics stock. The stock was sold at an average price of $14.35, for a total value of $86,100.00.
  • On Friday, September 15th, Christopher Haqq sold 6,000 shares of Atara Biotherapeutics stock. The stock was sold at an average price of $15.30, for a total value of $91,800.00.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) traded up $0.10 on Friday, hitting $14.60. The stock had a trading volume of 165,671 shares, compared to its average volume of 176,487. Atara Biotherapeutics, Inc. has a 1 year low of $11.80 and a 1 year high of $23.00.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($1.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.05). research analysts anticipate that Atara Biotherapeutics, Inc. will post -4 earnings per share for the current fiscal year.

WARNING: This report was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at https://www.watchlistnews.com/christopher-haqq-sells-1604-shares-of-atara-biotherapeutics-inc-atra-stock/1714431.html.

ATRA has been the subject of a number of research reports. Canaccord Genuity reiterated a “buy” rating on shares of Atara Biotherapeutics in a report on Thursday, November 9th. Jefferies Group LLC reiterated a “buy” rating and issued a $30.00 price objective on shares of Atara Biotherapeutics in a report on Thursday, October 5th. Zacks Investment Research cut Atara Biotherapeutics from a “buy” rating to a “hold” rating in a report on Monday, August 28th. Goldman Sachs Group, Inc. (The) reiterated a “neutral” rating and issued a $20.00 price objective on shares of Atara Biotherapeutics in a report on Friday, October 6th. Finally, BidaskClub cut Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, August 22nd. Three analysts have rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $24.40.

A number of hedge funds have recently modified their holdings of ATRA. SG Americas Securities LLC purchased a new stake in Atara Biotherapeutics during the 3rd quarter valued at about $142,000. Voya Investment Management LLC boosted its holdings in Atara Biotherapeutics by 16.2% during the 2nd quarter. Voya Investment Management LLC now owns 11,813 shares of the biotechnology company’s stock valued at $165,000 after acquiring an additional 1,651 shares during the period. Russell Investments Group Ltd. purchased a new stake in Atara Biotherapeutics during the 3rd quarter valued at about $170,000. State of Wisconsin Investment Board purchased a new stake in Atara Biotherapeutics during the 2nd quarter valued at about $252,000. Finally, The Manufacturers Life Insurance Company boosted its holdings in Atara Biotherapeutics by 7.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,377 shares of the biotechnology company’s stock valued at $285,000 after acquiring an additional 1,369 shares during the period. Institutional investors own 82.95% of the company’s stock.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.